The United States Anti-PD-1 Antibody Market accounts for the largest share of the regional landscape, supported by a strong oncology research ecosystem, high healthcare expenditure, and rapid adoption of advanced immunotherapies. Increasing incidence of melanoma, lung cancer, renal cell carcinoma, head and neck cancer, and other malignancies is fueling demand for Anti-PD-1 antibody therapies....